112 related articles for article (PubMed ID: 29979296)
21. Hypoglycemia and insulin analogues: is there a reduction in the incidence?
Heinemann L
J Diabetes Complications; 1999; 13(2):105-14. PubMed ID: 10432175
[TBL] [Abstract][Full Text] [Related]
22. Why Do Some Concentrated Insulins Maintain Their Pharmacokinetics/Pharmacodynamics Profile?
Hood RC
Diabetes Technol Ther; 2017 Apr; 19(4):203-205. PubMed ID: 28418731
[No Abstract] [Full Text] [Related]
23. Insulin degludec products approved for diabetes.
Traynor K
Am J Health Syst Pharm; 2015 Nov; 72(21):1834. PubMed ID: 26490811
[No Abstract] [Full Text] [Related]
24. Insulin glargine induced persistent intractable hypoglycemia, with variable presentations in older diabetic patients: an experience of 4 cases.
Kumari J; Dharmarajan TS
J Am Med Dir Assoc; 2009 Nov; 10(9):672-3. PubMed ID: 19883893
[No Abstract] [Full Text] [Related]
25. Insulin degludec--the impact of a new basal insulin on care in type 2 diabetes.
Khunti K; Cos X; Rutten G
Prim Care Diabetes; 2014 Jul; 8(2):119-25. PubMed ID: 24207030
[TBL] [Abstract][Full Text] [Related]
26. Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes.
Chatterjee S; Khunti K; Davies MJ
Drugs; 2019 Feb; 79(2):173-186. PubMed ID: 30623349
[TBL] [Abstract][Full Text] [Related]
27. Insulin analogues for recurrent severe hypoglycaemia.
Knip M
Lancet Diabetes Endocrinol; 2014 Jul; 2(7):529-30. PubMed ID: 24794702
[No Abstract] [Full Text] [Related]
28. A review of basal insulins.
Barnett AH
Diabet Med; 2003 Nov; 20(11):873-85. PubMed ID: 14632712
[TBL] [Abstract][Full Text] [Related]
29. Newer basal insulin analogues: degludec, detemir, glargine.
Kalra S
J Pak Med Assoc; 2013 Nov; 63(11):1442-4. PubMed ID: 24392539
[No Abstract] [Full Text] [Related]
30. Selected topics in the management of diabetes mellitus in cats.
Nelson RW
J Feline Med Surg; 2000 Jun; 2(2):101-4. PubMed ID: 11716601
[No Abstract] [Full Text] [Related]
31. Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
Buscemi S; Randazzo C; Buscemi C
J Diabetes Investig; 2019 Nov; 10(6):1595-1596. PubMed ID: 31135100
[TBL] [Abstract][Full Text] [Related]
32. Evolution of insulin development: focus on key parameters.
Tibaldi JM
Adv Ther; 2012 Jul; 29(7):590-619. PubMed ID: 22843207
[TBL] [Abstract][Full Text] [Related]
33. The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin.
Shaefer CF; Anderson J
Postgrad Med; 2016 Jan; 128(1):137-44. PubMed ID: 26548422
[TBL] [Abstract][Full Text] [Related]
34. [Regulation of labile diabetics with insulin Rapitard].
Kappeler HJ
Schweiz Med Wochenschr; 1966 Oct; 96(43):1450-6. PubMed ID: 5928766
[No Abstract] [Full Text] [Related]
35. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus.
Burge MR; Waters DL; Holcombe JH; Schade DS
J Clin Endocrinol Metab; 1997 Mar; 82(3):920-4. PubMed ID: 9062507
[TBL] [Abstract][Full Text] [Related]
36. Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: advances in clinical research.
Muñoz Torres M
Endocrinol Nutr; 2014 Mar; 61(3):153-9. PubMed ID: 23890782
[TBL] [Abstract][Full Text] [Related]
37. Understanding concentrated insulins: a systematic review of randomized controlled trials.
Ovalle F; Segal AR; Anderson JE; Cohen MR; Morwick TM; Jackson JA
Curr Med Res Opin; 2018 Jun; 34(6):1029-1043. PubMed ID: 29166786
[TBL] [Abstract][Full Text] [Related]
38. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M
Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471
[TBL] [Abstract][Full Text] [Related]
39. Lantus or lente insulin? The confusion builds.
Cohen MR
Nursing; 2003 Sep; 33(9):12. PubMed ID: 14562818
[No Abstract] [Full Text] [Related]
40. Preliminary study of protamine zinc recombinant insulin for the treatment of diabetes mellitus in cats.
Norsworthy G; Lynn R; Cole C
Vet Ther; 2009; 10(1-2):24-8. PubMed ID: 19742445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
